JBM Healthcare Logs Higher Profit in Fiscal 2024

MT Newswires Live06-18

JBM Healthcare (HKG: 2161) reported a profit attributable to the equity shareholders of around HK$130.5 million for the year ended March 31, 2024, as compared to HK$57.1 million from the previous fiscal year, a Tuesday filing with the Hong Kong Exchange said.

The companyâs earnings per share for the fiscal year 2024 came in at HK$0.1476 as compared to HK$0.0641 from the previous fiscal year.

The companyâs revenue for the reporting period was about HK$648.4 million, higher than the revenue of HK$520.3 million for the previous fiscal year, mainly attributable to a notable increase in revenues from the companyâs branded medicine segment, Chinese medicine segment, and health and Wellness products.

The company proposed a final dividend of HK$0.0405 per share for the year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2444335094?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-06-18 21:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2444335094","market":"sg","top_or_hot":-1,"title":"JBM Healthcare Logs Higher Profit in Fiscal 2024","media":"MT Newswires Live","content":"<html><body><p> JBM Healthcare (HKG: 2161) reported a profit attributable to the equity shareholders of around HK$130.5 million for the year ended March 31, 2024, as compared to HK$57.1 million from the previous fiscal year, a Tuesday filing with the Hong Kong Exchange said. </p><p>The companyâs earnings per share for the fiscal year 2024 came in at HK$0.1476 as compared to HK$0.0641 from the previous fiscal year. </p><p>The companyâs revenue for the reporting period was about HK$648.4 million, higher than the revenue of HK$520.3 million for the previous fiscal year, mainly attributable to a notable increase in revenues from the companyâs branded medicine segment, Chinese medicine segment, and health and Wellness products. </p><p>The company proposed a final dividend of HK$0.0405 per share for the year.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JBM Healthcare Logs Higher Profit in Fiscal 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJBM Healthcare Logs Higher Profit in Fiscal 2024\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-18 21:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>JBM Healthcare (HKG: 2161) reported a profit attributable to the equity shareholders of around HK$130.5 million for the year ended March 31, 2024, as compared to HK$57.1 million from the previous ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1606","symbol_name":"中医药概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2444335094","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2444335094","pubTimestamp":1718718105,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"JBM Healthcare  reported a profit attributable to the equity shareholders of around HK$130.5 million for the year ended March 31, 2024, as compared to HK$57.1 million from the previous fiscal year, a Tuesday filing with the Hong Kong Exchange said. The companys earnings per share for the fiscal year 2024 came in at HK$0.1476 as compared to HK$0.0641 from the previous fiscal year. The companys revenue for the reporting period was about HK$648.4 million, higher than the revenue of HK$520.3 million for the previous fiscal year, mainly attributable to a notable increase in revenues from the companys branded medicine segment, Chinese medicine segment, and health and Wellness products. The company proposed a final dividend of HK$0.0405 per share for the year.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1606":"中医药概念","BK1191":"制药","02161":"健倍苗苗","BK4137":"综合支持服务","HCSG":"医疗保健服务"},"translate_title":"JBM Healthcare 2024财年利润更高","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HCSG":1,"02161":0.9},"content_text":"JBM Healthcare (HKG: 2161) reported a profit attributable to the equity shareholders of around HK$130.5 million for the year ended March 31, 2024, as compared to HK$57.1 million from the previous fiscal year, a Tuesday filing with the Hong Kong Exchange said. The companyâs earnings per share for the fiscal year 2024 came in at HK$0.1476 as compared to HK$0.0641 from the previous fiscal year. The companyâs revenue for the reporting period was about HK$648.4 million, higher than the revenue of HK$520.3 million for the previous fiscal year, mainly attributable to a notable increase in revenues from the companyâs branded medicine segment, Chinese medicine segment, and health and Wellness products. The company proposed a final dividend of HK$0.0405 per share for the year.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2444335094"}